Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy

Internal Medicine

Volumn 48, Issue 9, 2009, Pages 665-672

  Minegishi, Yuji ^a   Takenaka, Kiyoshi ^a   Mizutani, Hideki ^a   Sudoh, Junko ^a   Noro, Rintaro ^a   Okano, Tetsuya ^a   Azuma, Arata ^a   Yoshimura, Akinobu ^a   Ando, Masahiro ^b   Tsuboi, Eitaka ^b   Kudoh, Shoji ^a   Gemma, Akihiko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Division of Internal Medicine   (Japan)

Author keywords

Acute exacerbation; Chemotherapy; Drug induced interstitial lung disease; Idiopathic interstitial pneumonias; Lung cancer

Indexed keywords

C REACTIVE PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEFITINIB; PACLITAXEL; PLATINUM COMPLEX; UFT; VINCA ALKALOID; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC INTERSTITIAL PNEUMONIA; INCIDENCE; INTERSTITIAL PNEUMONIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 67650070291     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1650     Document Type: Article

References (35)

1. Turner-Warwick M, Lebowits M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 35: 496-499, 1980.
2. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: caused and assessment. Am J Med 88: 396-404, 1990.
3. Hubbard R, Ven A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. Population-based cohort study. Am J Respir Crit Care Med 161: 5-8, 2000.
4. Park JS, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 17: 1216-1219, 2001.
5. American Thoracic Society. European Respiratory Society international multidisciplinary concensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165: 277-304, 2002.
6. Kawasaki H, Nagai K, Yokose T, et al. Clinicopathological characteristics of surgically resected lung cancer associated with idiopathic pulmonary fibrosis. Surg Oncol 76: 53-57, 2001.
7. Samet JM. Does idiopathic pulmonary fibrosis increase lung cancer risk? Am J Respir Crit Care Med 161: 1-2, 2000.
8. Hojo S, Fujita J, Yamadori I, et al. Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. Eur Respir J 12: 1404-1408, 1998.
9. Oshikawa K, Sugiyama Y. Serum anti-p53 autoantibodies from patients with idiopathic pulmonary fibrosis associated with lung cancer. Respir Med 94: 1085-1091, 2000.
10. Vassilakis DA, Sourvinos G, Spandidos DA, Siafakas NM, Bouros D. Frequent genetic alterations at the microsatellite level in cytologic sputum samples of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 162: 1115-1119, 2000.
11. Takahashi T, Munakata M, Ohtsuka Y, et al. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis. Cancer 95: 624-633, 2002.
12. Uematsu K, Yoshimura A, Gemma A, et al. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res 61: 8527-8533, 2001.
13. Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathological findings in three cases. Chest 103: 1808-1812, 1993.
14. Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 22: 821-826, 2003.
15. Akira M, Hamada H, Sakatani M, et al. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 168: 79-83, 1997.
16. Koizumi K, Hirata T, Hirai K, et al. Surgical treatment of lung cancer combined with interstitial pneumonia: the effect of surgical approach on postoperative acute exacerbation. Ann Thorac Cardiovasc Surg 10: 340-346, 2004.
17. Chiyo M, Sekine Y, Iwata T, et al. Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outocomes. J Thorac Cardiovasc Surg 126: 1141-1146, 2003.
18. Yuksel M, Ozyurtkan MO, Bostanci K, et al. Acute exacerbation of interstitial fibrosis after pulmonary resection. Ann Thorac Surg 82: 336-338, 2006.
19. American Thoracic Society. the European Respiratory Society International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165: 277-304, 2002.
20. Raghu G, Mageto YM, Lockhart D, et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 116: 1168-1174, 1999.
21. Nishimura K, Kitaichi M, Izumi T, et al. Usualinterstitial pneumonia: histologic correlation with high-resolution CT. Radiology 182: 337-342, 1992.
22. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177: 1348-1357, 2008.
23. Takeuchi E, Yamaguchi T, Mori M, et al. Characteristics and management of patients with lung cancer and idiopathic interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi 34: 653-658, 1996 (in Japanese).
24. Takenaka K, Okano T, Kamio K, et al. Acute exacerbation of idiopathic interstitial pneumonia complicated by lung cancer, Caused by Treatment for Lung Cancer. Haigan 39: 955-962, 1999 (in Japanese).
25. Hanibuchi M, Yamaguchi T, Okada T, et al. Clinical examination of acute exacerbation of idiopathic interstitial pneumonia (IIP) combined with lung cancer after anti-cancer treatment. Haigan 1: 281-286, 2001 (in Japanese).
26. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171: 1040-1047, 2005.
27. Thomas P, Castelnau O, Paillotin D, et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Francais de Pneumo-Cancerologie study. J Clin Oncol 19: 1320-1325, 2001.
28. Gridelli C, Manzione L, Perrone F, et al. Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. Br J Cancer 84: 38-41, 2001.
29. Mori K, Kamiyama Y, Kondo T, et al. Pilot pahase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer. Cancer Chemother Pharmacol 58: 86-90, 2006.
30. Gemma A, Seike M, Kosaihira S, et al. Phase I/II study of paclitaxel + carboplatin for refractory or recurrent non-small cell lung cancer. Anticancer Res 26: 3083-3087, 2006.
31. Fukushima K, Kawabata Y, Uchiyama T, et al. Prognosis of possible development into diffuse Interstitial pneumonia for 127 patients with localized usual interstitial pneumonia. Nihon Kokyuuki Gakkai Zassi 37: 177-182, 1999 (in Japanese).
32. Sheppard MN, Harrison NK. Lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitis. Thorax 47: 1064-1074, 1992.
33. Ziegenhagen MW, Zabel P, Zissel G, et al. Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am J Respir Crit Care Med 157: 762-768, 1998.
34. Suga M, Iyonaga K, Ichiyasu H, et al. Clinical significance of MCP-1 level in BALF and serum in patients with interstitial lung disease. Eur Respir J 14: 376-382, 1999.
35. Anscher MS, Peters WP, Reisenbichler H, et al. Transforming growth factor b as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 328: 1592-1598, 1993.